Ibnsina Pharma financials at a glance

+ Portfolio

The revenue of Ibnsina Pharma is reported as 22.2645 billion Pounds in the fiscal year 2023. The earnings were 0 Pounds per share in 2023, which was 4.35 lower than 2020. And about 0.16532 billion Pounds are reported as free cash flow in the financials of Ibnsina Pharma 2023. No dividends were paid to the shareholders of the Ibnsina Pharma stock CASE:ISPH in the financial year 2023.

Forecast

Financials

Year	Year	TTM	2021	2020	2019	2018	2017
Rev.	Revenue	N/A	£21.73B	£18.68B	£16.60B	£13.32B	£9.59B
GM %	Gross Margin %	7.58%	7.50%	7.85%	8.67%	8.44%	8.62%
OM	Operating Margin	2.96%	3.07%	2.62%	3.94%	3.50%	3.56%
EPS	Earnings Per Share	£0.00	£0.22	£0.23	£0.30	£0.22	£0.16
Div.	Dividends	N/A	£0.09	£0.05	£0.05	£0.05	£0.00
PR %	Payout Ratio %	0	40.91%	21.74%	16.67%	22.73%	0
Sha.	Shares	N/AM	1,226.04M	1,119.99M	1,119.99M	1,112.02M	1,042.43M
OCF	Operating Cash Flow	N/A	£-,340.43M	£588.07M	£-24.83M	£-,310.15M	£559.75M
FCF	Free Cash Flow	N/A	£-,487.96M	£357.94M	£-,378.31M	£-,742.77M	£363.13M
FCFS	Free Cash Flow Per Share	£0.01	£-0.45	£0.02	£-0.44	£-0.92	£0.31

Ibnsina Pharma financials at a glance

Financials

Discover